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Abstract 
 
Patients with Beckwith-Wiedemann syndrome (BWS) have an increased risk to develop 
cancer as a child, especially Wilms tumor and hepatoblastoma. The risk varies depending on 
the cause of BWS.  
We obtained clinical and molecular data in our cohort of children with BWS, including tumor 
occurrences, and correlated phenotype and genotype. We obtained similar data from larger 
cohorts reported in literature.  
Phenotype, genotype and tumor occurrence were available in 229 own patients. Minor 
differences in phenotype existed depending on genotype/epigenotype, similar to earlier 
studies. By adding patients from the literature we obtained data on genotype and tumor 
occurrence of in total 1971 BWS patients. Tumor risks were the highest in the IC1 
(H19/IGF2:IG-DMR) hypermethylation subgroup (28%) and pUPD subgroup (16%) and 
were lower in the KCNQ1OT1:TSS-DMR (IC2) subgroup (2.6%), CDKN1C (6.9%) 
subgroup, and the group in whom no molecular defect was detectable (6.7%). Wilms tumors 
(median age 24 months) were frequent in the IC1 (24%) and pUPD (7.9%) subgroups. 
Hepatoblastoma occurred mostly in the pUPD (3.5%) and IC2 (0.7%) subgroups, never in the 
IC1 and CDKN1C subgroups, and always <30 months of age. In the CDKN1C subgroup 
2.8% of patients developed neuroblastoma. 
We conclude tumor risks in BWS differ markedly depending on molecular background. We 
propose a differentiated surveillance protocol, based on tumor risks in the various molecular 
subgroups causing BWS.  
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INTRODUCTION 
 
Beckwith-Wiedemann syndrome (BWS) is an overgrowth disorder characterized by perinatal 
overgrowth, macroglossia, exomphalos, hemihyperplasia and postnatal hypoglycemia, and 
associated with an increased risk to develop embryonic tumors.
1,2 
The prevalence at birth is 
estimated to be 1/12,000.
3
 Two sets of similar but not identical diagnostic criteria are mainly 
used in clinical practice  (Table I).
4,5
 
Familial transmission has been reported as occurring in ∼15 percent of BWS patients if 
all patients were grouped together.
6
 BWS exhibits etiologic molecular heterogeneity due to a 
variety of alterations in growth regulating genes located at chromosome 11p15. This 
chromosome region harbors two independently regulated clusters of imprinted genes (Fig. 1). 
One cluster contains the reciprocally imprinted genes IGF2 and H19 and is under control of 
H19/IGF2:IG-DMR (IC1), upstream of the H19 promoter.
7 
This imprinting center is 
differentially methylated, methylation being present only at the paternal allele. The second 
cluster contains (among others) the maternally expressed CDKN1C gene and the paternally 
expressed KCNQ1OT1 (LIT1) gene and is under control of  KCNQ1OT1:TSS-DMR (IC2), 
located upstream of the KCNQ1OT1 promoter. This region is methylated on the maternal 
allele only. The majority of BWS patients (80%) show an aberrant imprinting in either one, or 
both imprinted clusters (choufani 2013).
8
 Aberrant methylation of both ICs is typically 
explained by a paternal UniParental Disomy (pUPD) of the 11p15 region (20% of BWS 
cases). Mutations in CDKN1C are found in approximately 5-10% of (mostly familial) cases. 
Infrequently paternal trisomy of 11p15 or a maternal balanced translocation involving the area 
causes BWS. Approximately 10-15% of cases remain without molecular confirmation of the 
syndrome despite carrying all clinical characteristics of the syndrome.
9 
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BWS patients have an increased incidence of embryonic tumors, especially Wilms 
tumors, but also hepatoblastoma, neuroblastomas, adrenal carcinomas and 
rhabdomyosarcomas can occur.
5,10-16 
This risk depends on the epigenetic defect of BWS: 
patients with a molecular abnormality involving the telomeric domain (pUPD) and H19 gain 
of methylation [GOM]) tend to have a higher risk
 
patients with an abnormality involving the 
centromeric domain (CDKN1C mutations and  loss of  KCNQ1OT1 methylation [LOM]) tend 
to develop tumors infrequently.
14,16,17
  Several protocols have been suggested for tumor 
surveillance, consisting typically of abdominal ultrasound and screening of alfa-fetoprotein 
levels at various ages and intervals.
16, 18-25
 All protocols have been based on relatively small 
groups of patients, and with a limited number of exceptions subtype of BWS were not taken 
into account for the surveillance protocol.
14-16,26,27
 
Here we report on studies in a large cohort of BWS individuals, summarize their phenotype, 
add data from similar studies in literature in order to correlate the phenotype with the various 
genetic subgroups in BWS. We determined the relative tumor risks for each of these 
subgroups, and propose a tumor surveillance system.   
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METHODS  
Patient selection 
The Academic Medical Center in Amsterdam started to offer cytogenetic and molecular 
diagnostics tests for BWS in the early nineties. Since 2000 it functions as the national center 
of referral for individuals with BWS. Any patient who fulfilled the diagnostic criteria 
described by DeBaun and/or Elliott (Table I) was allowed to enter the study, irrespective 
whether the clinical diagnosis BWS could be confirmed molecularly or not.
4,5
  
Clinical data of all included patients were obtained either directly by examining patients, or 
through questionnaires on clinical manifestations forwarded to physicians who submitted 
samples of patients suspected for having BWS.  In 2005 a dedicated outpatient clinic was 
opened specifically for individuals with BWS. A single clinical geneticist (SMM) evaluated 
all individuals referred to this clinic, and extensive initial and follow-up data were collected. 
For the present study the Dutch Childhood Oncology Group pediatric was consulted in June 
2015, in order to evaluate whether, since the last clinical contact, a tumor had developed in 
any of our patients. In all patients with a tumor the major characteristics of that tumor were 
obtained.   
 The Medical Ethics Committee of our institution approved this study (#99.15.210). 
Informed consent was obtained from all participating patients and/or their parents/legal 
representatives. 
 
Molecular analysis  
Studies were performed at the Molecular diagnostics Laboratory of the Academic Medical 
Centre in Amsterdam. DNA was extracted from peripheral blood lymphocytes and 
methylation levels of KCNQ1OT1 and H19 were determined by either southern blot 
methylation sensitive high resolution melting analysis (HRMA)
28
 or methylation multiplex 
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ligation-dependent probe amplification (MLPA).
29
 In case of loss of imprinting of both 
KCNQ1OT1 and H19, variable number of tandem repeats (VNTR) studies were performed to 
confirm the presence of pUPD, as described before.
28
 Mutation analysis of CDKN1C was not 
performed routinely. Study participants were classified in 4 genetic subgroups: 
hypermethylation of H19/IGF2:IG-DMR (further indicated in the manuscript as IC1); 
hypomethylation of KCNQ1OT1:TSS-DMR (further indicated in the manuscript as IC2); 
pUPD; and clinical diagnosis fulfilling the diagnostic criteria of either DeBaun and/or Elliot 
and without detectable genetic abnormality. 
 
Literature study 
A literature search was performed in Pubmed and EMBASE with MESH terms: (neoplasms 
OR cancer* OR tumor OR tumors OR tumour* OR Wilms OR hepatoblastoma) AND 
(Beckwith-Wiedemann syndrome OR Beckwith-Wiedemann) AND (genetics OR genetic* 
OR phenotyp* OR genotyp* OR epigenotyp*). The reference lists of all publications were 
hand-searched for other potentially useful publications. Case reports were excluded: we 
included only studies with series of patients of whom phenotype, genotype and tumor 
characteristics were described. Only tumors that are considered to be malignant and thus 
listed in the International Classification of Childhood Cancer (ICC3) have been included.
30
 
We have carefully avoided using patient data more than once as in several publications data of 
earlier publications were incorporated. If needed this has been checked specifically by 
contacting the authors of the original publications.   
 
Statistical analysis  
The Statistical Package for the Social Sciences (IBM SPSS version 22.0, USA) was used to 
analyze the data. Descriptive statistics were generated to describe the total sample of patients 
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and the subsamples of genetic subgroups. Differences between the genetic subgroups were 
tested with ANOVA for parametric data, and Chi-squared tests statistics for non-parametric 
data. Fisher’s exact test was used when appropriate. Two-tailed P-values <0.05 were 
considered to indicate statistical significance. 
 
 
RESULTS  
 
Characteristics of own study group 
In total 244 patients were included in this study. Five patients had a chromosome abnormality 
and were excluded as the other chromosome imbalances prohibited analysis of the phenotype 
due to only a 11p15 imbalance. All patients but three were at least five years of age when last 
data were gathered (mean 15.2 years, median 13.5 years). The distribution over the four 
genetic subgroups is provided in Table II, in which also the frequencies of manifestations of 
BWS in the genetic subgroups and in the total patient group are available. The various 
abnormal morphological characteristics are available in Supplemental Table S-I.  
 
Tumor frequencies in own study group and in literature cohorts  
We were able to obtain reliable data on both genotype and tumor occurrence in 229 BWS 
patients of the present cohort (Table III). The literature search yielded seven studies in which 
cohorts of patients with BWS were described including the various genetic subgroups and 
tumors (Weksberg et al., 2001; Gaston et al., 2001; DeBaun et al., 2002; Bliek et al., 2004; 
Brioude et al., 2013; Ibrahim et al., 2014; Mussa et al., 2015). 
5,12,13,16,17,27,31
 
In three cohorts not all BWS patients were screened for CDKN1C mutations
5,13
, and in 
two other studies (Brioude et al., 2013; Mussa et al., 2015) BWS patients in whom no 
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molecular defect could be detected were not included.
16,27
 We decided to include these five 
studies in the overview to increase the number of useful data even though this means that the 
numbers of individuals and tumors in the genetic subgroups ‘CDKN1C’ and ‘no detectable 
molecular cause’ are minimum estimates. In total data on 1971 BWS patients were available. 
The highest tumor risk was present in the genetic subgroup IC1hypermethylation (28%), the 
lowest tumor risk was in the subgroup with IC2 hypomethylation (2.6%). These risks are at 
the age patients were described, which varied among the various publications. The exact 
nature of tumors occurring per genetic subgroup is listed in Table III. The risk for specific 
tumors in the subgroups (IC2, IC1, pUPD, no defect, CDKN1C) were for Wilms tumor 0.2%, 
24%, 7.9%, 4.1%, and 1.4%, for hepatoblastoma 0.7%, 0%, 3.5%, 0.3%, and 0%, and for 
neuroblastoma 0.4%, 0%, 1.4%, 0.6% and 2.8%, respectively. For all other specific tumor 
types the risk per molecular subgroup was well below 1% (Table III). In addition we studied 
the age at which BWS patients developed a tumor. If available both mean and median age is 
provided, and the highest age at which a tumor was detected per genetic subgroup (Table IV).
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DISCUSSION  
 
BWS is often diagnosed by combining clinical and molecular findings. Two generally 
accepted sets of diagnostic criteria are those described by Elliott
4
 and DeBaun
5
 (Table II). The 
Elliott criteria are usually stricter than the DeBaun criteria, and also in our series all patients 
fulfilled the DeBaun criteria while 43.8% of patients fulfilled the Elliott criteria. In the series 
of patients published by Ibrahim and co-workers (Ibrahim) the sensitivity of the DeBaun 
criteria were calculated to be higher than the Elliott criteria (83.5% versus 43.5% ), and 
specificity were 83.5% (Elliot criteria) versus 62.3% (DeBaun criteria).
30 
Whether in the 
present cohort the specificity of either set of criteria is higher than the other remains uncertain 
as we have no information on how frequently samples of patients fulfilling either set of 
criteria are indeed submitted for molecular analysis. We found in the present study that more 
than half of patients (varying from 50% to 58.4%) in whom a molecular diagnosis of BWS 
could be made did not fulfill the Elliott criteria. As reported previously
13, 31
 there is also a 
subgroup of patients with a clinical diagnosis of BWS but no detectable molecular 
abnormality.
13,31
 In this group the percentage of patient that did not fulfill the Elliott criteria 
(56.4%) was similar to that in the other patient groups (with a detectable molecular cause). 
We conclude that the sets of diagnostic criteria are both useful, but for neither of the sets do 
we know with certainty that sensitivity and specificity are truly high. BWS was and still is a 
clinical diagnosis, in which a molecular confirmation is not always possible, and further 
studies of the Elliott and DeBaun criteria and other sets of criteria are needed.  
 
Clinical features of BWS  
The phenotype of the present cohort is, in general, comparable to that in patients described in 
other cohorts.
16,27
 As can be expected the patients in the group ‘clinical diagnosis’ show the 
Page 9 of 40
John Wiley & Sons, Inc.
American Journal of Medical Genetics: Part A
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 10
signs that are very characteristic for BWS somewhat more frequently than the patients with a 
molecular abnormality, as the former patients were diagnosed based on the phenotype only 
(Table II). Remarkable differences between the various groups are the lower frequency of a 
high birthweight in the IC2 hypomethylation subgroup, the high frequency of asymmetrical 
overgrowth in the pUPD subgroup (as described before) and explained by mosaicism for the 
pUPD), and the relatively low frequency of ear creases, ear pits and facial naevus flameus in 
the IC1 hypermethylation subgroup.
 5,12,14,16,31,32
 Also, as reported previously, a low frequency 
of omphalocele in this latter subgroup was found, and less frequently an enlargement of the 
internal organs (especially kidney and spleen) in the IC2 hypomethylation subgroup.
32,33
 
Though not all data was collected by evaluating the cohort personally, the vast majority of 
cases were seen and examined and so the data in Table II is likely to be very reliable.  
 
Neoplasia  
In the present cohort we have found the highest risk to develop cancer in the IC1 
hypermethylation subgroup, and to a lesser extend in the pUPD group. In the IC2 
hypomethylation subgroup two children with a Wilms tumor were found, which has not been 
reported before. Niemitz et al. have described two patients with a Wilms tumor and 
hypomethylation of KCNQ1OT1 in normal kidney tissue and LOH in the tumor, but 
unfortunately details regarding methylation results in lymphocytes were not provided.
34
 
We provide a complete literature overview evaluating almost 2000 BWS patients, which 
allows reliable conclusions (Table III). Earlier careful meta-analyses of the literature are 
available, but in much smaller numbers.
15,27
 We realize there is likely still a publication bias 
in data reported in literature, and in reality frequencies may be somewhat lower.  
We evaluated the nature of the tumors in our own patients and patients reported in literature. 
Wilms tumors and hepatoblastoma are only rarely present in the IC2 hypomethylation 
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subgroup, and Wilms tumors are also very unusual in the CDKN1C group. In all other 
molecular groups Wilms tumors are frequently occurring. In the IC2 hypomethylation 
subgroup the variability in tumor types is remarkably large. In the IC1 group no 
hepatoblastoma has ever been described. In the CDKN1C group reported by Gaston et al.
12
 
and Brioude et al.
16
 individuals developed neuroblastoma at age 6m and 10m, respectively. 
The median age at which BWS individuals develop cancer in the present cohort has been 24 
months for Wilms tumors and 12 months for hepatoblastoma. There is a tendency for Wilms 
tumors to develop at an earlier age in the IC2 subgroup compared to the IC1 and pUPD 
groups. Results are compared to literature data in Table IV. 
Cancer risks in BWS have been reported correlated with the presence of 
hemihyperplasia, nephromegaly, nephrogenic rests and nephroblastomatosis.
1,33,35
 Mussa et 
al.
32
 found hemihyperplasia and enlarged kidneys in all patients with a Wilms tumor, and 
similarly DeBaun
10
 reported that all patients with a Wilms tumor had enlarged kidneys if 
evaluated repeatedly. In this publication before molecular subgroups could be made, the 
nephromegaly was typically bilateral, and the cancer had always arisen in the largest kidney.
10
 
Gaston et al. found a (statistically insignificant) higher frequency of hemihyperplasia in 
patients with tumors but this was not subdivided according to molecular subtype.
12 
We 
evaluated this in our cohort according to different molecular genetic subgroups: Wilms 
tumors were more frequently found in each of the genetic subgroups except for the IC2 
subgroup where there is no difference (Supplemental Table S-2). However, for none of the 
subgroups was this difference statistically significant. In the pUPD group there was a 
statistically significant increase of hemihyperplasia in the group who developed a Wilms 
tumor, and this was also found in the group in whom no molecular defect could be detected 
causing BWS. In the latter group there was also a significantly more frequent occurrence of 
an enlarged spleen (p=0.016). Otherwise in none of the subgroups a marked difference was 
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found for the occurrence of Wilms tumors and the presence of hemihyperplasia, enlarged 
livers or spleens, or combinations of these. We realize the various subgroups are small and 
these conclusions should be used with caution. We refrained from performing similar 
comparisons with hepatoblastoma due to the very small numbers. 
 
Screening: General considerations 
Screening individuals for cancer is aimed at improving the outcomes for those who have an 
increased genetic risk to develop tumors.
24  
The outcomes can improve by detecting tumors 
earlier, at a less advanced stage than they would have at detection without screening. Less 
advanced tumors generally need less extensive surgery and less intensive chemo- and 
radiotherapy, and are associated with a better survival.
24
 A prerequisite is that the screening 
schedule is as such that indeed the tumor is detected at a less advanced stage, so the velocity 
of the growth of the tumor, the sensitivity and specificity of the screenings procedure, the 
interval between the screening moments, the treatment schedules of the various stages of the 
tumor, and the effectiveness of these treatment schedules need to be carefully determined.
36
 
Screening has significant consequences for the emotional wellbeing of patients and their 
families. It can be positive for them knowing they are being controlled but it can also create 
recurrent anxieties around each screening moment. Screening can lead to false negative and 
false positive results. The latter may need additional evaluations and infrequently surgical 
procedures, with obvious and significant impact on the wellbeing of patients and their 
families.
19,20
 
The threshold level above which the risk to develop cancer is sufficiently high to 
provide surveillance is a subjective decision.  The UK Wilms Tumor Surveillance Working 
Group suggested that surveillance should be offered to children who are at a greater risk than 
5% risk of Wilms tumor.
37
 Other studies did not mention specifically a threshold Wilms 
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tumor risk for inclusion in surveillance, though in practice a 5% threshold for a general tumor 
risk was used. We have followed these authors and use the threshold level of 5% risk for all 
tumors together and, admittedly somewhat arbitrarily, added a 2% risk as threshold to screen 
for specific tumors. 
Screening has financial implications. In most countries these are limited for the 
patients and their families themselves, but these may be significant for society. A cost-
effectiveness evaluation should be part of general evaluations of screening procedures.
38
 
The total of the above influences on screening should be used to weigh the potential benefits 
and disadvantages of any screening schedule, and to establish protocols that address 
adequately the needs of the population under screening. An overview of the earlier reported 
recommendations in BWS in which the various molecular pathogeneses have been taken into 
account, is provided in Table V. 
 
Background for Wilms tumor screening 
Wilms tumors are embryonal kidney tumors that are almost invariably present before 10 years 
of age.
19
 The median age of identification of Wilms tumors in our cohort is 18 months and of 
all studies together it is 24 months. Exceptionally Wilms tumors have been reported in BWS 
patients over 5 years of age, including at 10 years,
32
 12 years,
12,16
 and 13 years in a patient 
with a cytogenetically visible deletion of 11p13.
39
 Long-term survival in Wilms tumors is 
>90% for localized tumors and >70% for advanced tumors.
40
 Advanced stage Wilms tumors 
need more intensive chemotherapy and radiotherapy.
41 
Detection of Wilms tumor at an earlier 
stage reduced treatment-related morbidity in some studies 
22,42
 but not in others.
43,44
 No results 
of reliable studies are available that show that early detection has a significant impact on the 
overall survival of BWS individuals. Craft et al. reported lack of a difference in outcome or 
stage distribution of the tumor between screened and unscreened population screening.
44
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False positive results of screening have been reported such as cysts, nephrogenic rests 
or foci of renal dysplasia.
19,42
 The doubling time estimated for growth rate in Wilms tumors is 
11-40 days.
45-47
 This rapid tumor growth indicates only an interval of three and four months 
between screening moments is appropriate. McNeil et al. concluded that ultrasound screening 
of the abdomen at least until the age of 7 years is a cost-effective method to screen BWS 
patients if one considers costs of the screening and costs of treating a low stage tumor versus a 
late stage tumor.
38
 
 
Background for hepatoblastoma screening 
Hepatoblastomas are malignant liver cancers that consist of fetal liver cells, more mature liver 
cells and bile duct cells.
48
 Ninety percent of hepatoblastomas occur before the age of four 
years, at a mean age of 22 months and median age of 16 months, and only exceptionally at an 
older age.
49
 In BWS all hepatoblastoma occurred <30months of age (Table IV).
50
  We have 
been unable to find a reliable description of an exception. In children with BWS it was shown 
that hepatoblastoma was diagnosed at a significantly younger age (median age 6 months) 
compared to children with hepatoblastoma without BWS (median age 16 months), and also 
the stage at diagnosis tended to be lower.
50 
All patients are treated with chemotherapy and a 
surgical resection is attempted after tumor shrinkage.
24
 After complete resection patients have 
an event-free survival of > 90%.
51
 Patient with tumors that are initially non-resectable have an 
event-free survival rate of <70%, and those with metastases have an event-free survival rate of 
20-30%.
51,52
 Thus, early detection by effective screening could lower tumor advancement and 
treatment-related morbidity.
50,53
 In over 96% of patients with hepatoblastoma serum alpha-
fetoprotein (AFP) levels are elevated. Since AFP levels tend to be elevated in BWS 
individuals anyway, this urges for careful interpretation of screening results to avoid false 
positive results.
22,40,54
 AFP levels can be elevated when abdominal ultrasounds do not allow 
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visualization of a tumor, 
40,55 
and especially a rise of AFP levels after a few weeks is a strong 
indicator for further evaluations.
40
 Rojas et al. reported on a small series of patients with 
hepatoblastoma who were screened for recurrences.
56 
They found that AFP was elevated 1-
11months before the tumor was detected by the surveillance imaging, and also reported false 
positive results. A similar study showed AFP to be elevated until two months before imaging 
showed an abnormality, and these authors reported on false negative results.
57 
The half-life of 
AFP is 5-6 days.
58
 Hepatoblastoma can grow very rapidly, doubling time has been reported as 
low as a few weeks.
22 
 
Authors of several early publications have concluded the usefulness of AFP screening 
should be doubted due to interpretation difficulties,
59
 uncertainty whether it allows discovery 
of hepatoblastoma at such an earlier age that this changes prognosis, the relatively low 
occurrence of hepatoblastoma in BWS individuals, and the need for very frequent sampling 
for AFP for a potentially useful surveillance.
16,22,59
 
 
Background for neuroblastoma screening 
Neuroblastoma is a common pediatric cancer arising from the developing sympathetic 
nervous system, and can follow a highly variable course, from spontaneous regression to 
aggressive metastatic tumors. Neuroblastoma are usually diagnosed between 0 and 4 years of 
age (median 19 months).
 60
 Less than 5% occur at 10 years of age or above.
61
 A 
neuroblastoma can be classified as low risk, intermediate risk and high risk depending on age, 
stage, histopathology, DNA index (ploidy) and MYCN amplification.
62
 Depending on the 
stage, treatment consists of surgery combined with chemotherapy, radiotherapy, and more 
recently immunotherapy. Survival of low and intermediate risk is excellent (90%) but for high 
risk neuroblastoma this is only 40-50%.
63
 Homovanillic acid and vanillylmandelic acid (HVA 
and VMA) are good biomarkers to detect neuroblastoma.
64 
Population screening resulted in 
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increased detection of tumors but these were tumors with favorable biology and 
pathology.
65,66
 For conditions with a high risk for neuroblastoma such as in the NPARM 
group of PHOX2B mutations, ultrasound of the abdomen and urinary VMA and HVA every 
three months until the age of two years has been recommended and subsequent screening was 
depending on the risk on developing tumor.
61
 
 
Screening proposal 
The earlier suggested surveillance protocols for individuals with BWS in which molecular 
subgroups were taken into account, are summarized in Table V. They differ in screening 
methods, frequency and duration. We add to these an amended surveillance protocol based 
on:  
a. The marked differences of occurrence of tumors in the various molecular genetic subgroups 
which indicate that the molecular background needs to be taken into account. 
b. Screening is indicated in BWS patients with a IC1 hypermethylation, pUPD, and no 
detectable molecular abnormality, but not in BWS patients with a IC2 hypomethylation as in 
the latter patients the risk to develop a tumor is 2.6%. Raising the awareness of physicians in 
charge of BWS individuals with a IC2 epimutation that there is only a small increased chance 
of developing a tumor is indicated. 
c. The number of reported BWS patients with a CDKN1C mutation is too low to determine 
the risk for tumor development in general, and for separate risks for Wilms tumors, 
hepatoblastoma, and neuroblastoma with certainty. We suggest to offer screening to the 
families, with a full explanation of the benefits and drawbacks. If a family decides for tumor 
screening we suggest to offer a complete screening. For Wilms tumor and hepatoblastoma the 
screening can therefore be the same screening as for BWS patients with a pUPD.  
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d. The presence or absence of hemihyperplasia, enlarged liver and/or spleen and/or kidney 
does not alter the screening protocol. 
e. BWS patients with a IC1 hypermethylation should only be screened for Wilms tumors as 
hepatoblastoma does not occur; patients with pUPD or no detectable molecular abnormality 
should be screened for both Wilms tumors and hepatoblastoma. 
f. Based on doubling time for growth rate screening for Wilms tumors should be performed 
every 3 months. Based on median and mean age of occurrence of Wilms tumors, screening is 
indicated from birth until age five years. The frequency of all type of tumors after age 4 years  
is well below 5% for each study individually and for each molecular genetic subgroup, and 
we do not advocate screening for this age group.  
g. Presence of Wilms tumors is screened by renal sonographies although local circumstances 
may make MRI screening more useful. 
h. Based on doubling time for growth rate screening for hepatoblastoma should be performed 
every 3 months. Based on the median and mean age of occurrence of hepatoblastoma 
screening is indicated between 0 and 36 months of age. As screening for Wilms tumors by 
imaging is indicated until 48 months, in practice abdominal imaging including both kidneys 
and liver will be performed simultaneous until that age in patients with pUPD, CDKN1C and 
those with no detectable molecular abnormality. 
i. Existence of hepatoblastoma is screened by liver sonographies although local circumstances 
may make MRI screening more useful. We do not advocate AFP screening as there is 
insufficient proof this screening changes morbidity or mortality of BWS patients who develop 
a hepatoblastoma, while the burden of repeated blood sampling in young children and 
consequences for the emotional well-being for the families is considerable. We do not 
advocate abdominal palpation by parents because we concur with others that this may 
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exacerbate parental anxiety and affect parent-child relationship, especially if a mass is not 
detected during “ parental surveillance”.
40
 
j. The presence of neuroblastoma can be screened by urinary excretion of VMA and HVA and 
abdominal ultrasound every three months until the age of two years. Due to the relatively low 
risk and early age of patients in whom neuroblastoma have been found we do not advocate 
screening in older children.   
k. We realize that the presently suggested surveillance protocol may need adaptation if 
markedly more BWS patients are reported in sufficient detail. Especially the screening for 
BWS patients with a CDKN1C mutation may need adaptation if such data would be available. 
Two additional studies describing larger series of patients with CDKN1C have been reported, 
including the occurrence of tumors, increasing the number of CDKN1C patients to 93, while 
the number of patients with cancer remained 6 (6.4%).
67,68
 This may indicate that if a 
sufficiently large number of BWS patients with a CDKN1C mutation are reported, the tumor 
risk may be below 5% and surveillance may not be indicated. We also realize no screening 
protocol will detect every tumor and occasionally a tumor will develop in a BWS child in 
whom surveillance is discontinued; this is an inescapable characteristic of screening if the 
screening procedure has disadvantages as well, which is invariably the case.
40
 
 
CONCLUSIONS 
We show that tumor risk may vary considerably in genetic subgroups of BWS as some 
subgroups have a high risk of developing a Wilms tumor or hepatoblastoma while others have 
a low risk. Current screening protocols usually do not take this into account. We therefore 
propose a new screening protocol that is based on our own experience and an overview of 
literature, and offers a state-of-the-art of 2015. We realize that several important issues are 
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still insufficiently studied, such as the burden of screening for BWS children and their 
families, and the influence this has on their wellbeing. Also the proof that in each molecular 
subgroup morbidity and mortality is changed sufficiently to counterbalance disadvantages is 
almost completely lacking. Until such studies are available we hope the present overview and 
surveillance protocol will be of benefit to the BWS children and their families. 
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LEGENDS 
 
Figure 1. Schematic representation of the imprinting control regions (ICR) on 
chromosome 11p15. BWSIC1 contains the reciprocally imprinted embryonic growth factor 
IGF2 (expressed from paternal allele) and the noncoding RNA H19 (expressed from maternal 
allele). Disturbance of the IC1 methylation results in overexpression of IGF2. BWSIC 2 
contains the cell-cycle inhibitor CDKN1C and the noncoding RNA KCNQ1OT1 (expressed 
from the paternal allele). Mutations in CDKN1C (expressed from the maternal allele) and 
disturbance of methylation at IC2 results in reduced expression of CDKN1C. Both IC1 and 
IC2 can be disturbed in BWS, resulting in embryonic overgrowth. Note that the sizes and 
distances are not drawn to scale. 
 
Figure 2. Suggested surveillance in patients with Beckwith-Wiedemann syndrome depending 
on molecular subgroup. 
   
 
Table I. Two major sets of diagnostic criteria used for Beckwith – Wiedemann 
Syndrome.  
 
 
Table II. Phenotype in 244 patients with Beckwith-Wiedemann syndrome comparing 
overall phenotype to those in the various genetic subgroups. 
 
 
Table III. Overview of cohorts of individuals with Beckwith-Wiedemann syndrome and 
frequencies of tumors in genetic subgroups. 
 
Table IV.  Overview of age at detection of tumors in cohorts of individuals with 
Beckwith-Wiedemann syndrome. 
 
Table V. Overview of suggested screening protocols taking molecular subgroups into 
account. 
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Figure 1. Schematic representation of the imprinting control regions (ICR) on chromosome 11p15. BWSIC1 
contains the reciprocally imprinted embryonic growth factor IGF2 (expressed from paternal allele) and the 
noncoding RNA H19 (expressed from maternal allele). Disturbance of the IC1 methylation results in 
overexpression of IGF2. BWSIC 2 contains the cell-cycle inhibitor CDKN1C and the noncoding RNA 
KCNQ1OT1 (expressed from the paternal allele). Mutations in CDKN1C (expressed from the maternal allele) 
and disturbance of methylation at IC2 results in reduced expression of CDKN1C. Both IC1 and IC2 can be 
disturbed in BWS, resulting in embryonic overgrowth. Note that the sizes and distances are not drawn to 
scale.  
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Table I. Two major sets of diagnostic criteria used for Beckwith – Wiedemann Syndrome.  
 
 DeBaun et al. (2002) Elliot et al. (1994) 
 
Beckwith-Wiedemann 
syndrome present if:  
 
 
a. clinical diagnosis by physician, and 
b. at least 2 criteria present  
 
 
a. at least 3 major features present, or      
b. 2 major + 3 or 4 minor criteria present 
 
Birth weight > 90
th
 centile 
criterion Major 
Macroglossia 
criterion Major 
Abdominal wall defect criterion Major 
Postnatal hypoglycemia 
criterion Minor 
Ear creases or ear pits 
criterion Minor 
Hemihyperplasia 
- Minor 
Nephromegaly 
- Minor 
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Table II. Phenotype in 244 patients with Beckwith-Wiedemann syndrome comparing overall phenotype to those in the various 
genetic subgroups        
_________________________________________________________________________________________________________________________________________________________________ 
    Total   IC2 LOM  IC1 GOM  pUPD   clinical diagnosis p-value 
      (%)           (%)      (%)     (%)         (%) 
_________________________________________________________________________________________________________________________________ 
Number   244        (100%) 125        (51.2%) 20      (8.2%)  44       (18%)  55      (22.5%) 
Gender (M:F)   112:132  57:68   10:10   21:23   24:31 
Criteria Elliott
1
   107/244 (43.8%) 52/125   (41.6%) 10/20 (50%)  21/44  (47.7%)  24/55 (43.6%)  0.477 
 
Growth 
Birth weight>90
th
 centile 167/172 (97%)  44/85     (51.8%) 11/15 (73.3%)  28/32  (87.5%)  29/40 (72.5%)  0.002  
Hemihyperplasia  103/223 (46.2%) 38/ 115  (33%)  11/19 (57.9%)  36/42  (85.7%)  18/47 (38.3%)  <0.001 
 
Facial 
   Macroglossia   198/240 (82.5% ) 106/123 (86.2%) 17/20 (85%)  34/43  (79.1%)  41/54 (75.9%)  0.361 
   Ear creases   76/229   (33.2%) 40/ 119 (33.6%) 2 /18  (11.1%)  13/40  (32.5%)  21/52 (40.4%)  0.158 
   Ear pits   47/222  (21.2%) 28/114  (24.6%) 1/ 19  (5.3%)  11/ 39 (28.2%)  7/50   (14%)  0.095 
   Facial naevus flammeus 100/226 (44.2%) 63/ 118 (53.4%) 3/20   (15%)  14/39  (35.9%)  20/49 (40.8%)  0.007 
   Other dysmorphic signs
2
 44/152  (28.9%) 15/ 76   (19.7%) 5/14   (35.7%)  9/32    (28.1%)  15/30 (50%)  0.019 
 
Abdomen 
   Abdominal wall defect 
 Omphalocele  52/235   (22.1%) 39/122 (32%)  0/20   (0%)  5/39    (12.8%)  8/54   (14.8%)  0.001 
 Umbilical hernia  100/223 (44.8%) 50/114 (43.9%)  8/20   (40%)  16/38  (42.1%)  26/51 (51%)  0.771 
 Diastasis recti  100/199 (50.2%) 20/103 (19.4%)  6/18   (33.3%)  8/34    (23.5%)  12/44 (27.3%)  0.516 
   Nephromegaly  56/210   (26.7%) 14/106 (13.2%)  8/20   (40%)  17/38  (44.7%)  17/46 (37%)  0.000 
   Hepatomegaly  44/208   (21.2%) 19/109 (17.4%)  4/20   (20%)  7/34    (20.6%)  14/45 (31.3%)  0.308 
   Splenomegaly  21/204   (10.3%) 8/104   (7.7%)  3/20   (15%)  4/34    (11.8%)  6/46   (13%)  0.637 
 
Other 
   Cardiac anomaly
3
  22/215  (10.2%) 17/109 (15.6%)  1/ 20  (5%)  2/39    (5.1%)  2/47  (4.3%)  0.074 
   Hypoglycemia  89/147   (60.5%) 44/ 70  (62.9%)  6/ 13  (46.2%)  20/30  (66.7%)  19/34 (55.9%)  0.559    
   Developmental delay  18/179  (10%)  7/87     (8%)  1/19   (5.3%)  2/34    (5.9%)  8/39   (20.8%)  0.148 
 
1
 All patients fulfilled the diagnostic criteria of DeBaun et al (2002)  
2
 A full list of all other signs is available as Supplemental material Table S-I.  
3
 VSD (n=5), ASD (n=4), persistent ductus arteriosus (n=2), open foramen ovale (n=2), pulmonic stenosis (n=1), cardiomyopathy with thickened ventricle septum 
(n=1), septum hypertrophy (n=1) valvular aorta stenosis (n=1)  
LOM = loss of methylation; GOM = gain of methylation 
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Table III. Overview of cohorts of individuals with Beckwith-Wiedemann syndrome and frequencies of tumors in genetic subgroups. 
Study N  Tumors  per subgroup Tumor type 
Weksberg et al., 2001 125 
 
 
 
IC2                 5/35
1
  
IC1                 1/3      
UPD               6/21    
No defect       4/17
2 
CDKN1C        0/5 
2 hepatoblastoma, 2 rhabdomyosarcoma, 1 gonadoblastoma 
1 Wilms 
5 Wilms, 1 hepatoblastoma 
4 Wilms 
none
 
Gaston et al., 2001 
 
97
3 
IC2                 1/45    
IC1                 5/11    
UPD               4/11
4
  
No defect       1/24   
CDKN1C        1/2    
1 thyroid carcinoma (11yr) 
4 Wilms, 1 ganglioneuroma 
2 Wilms, 1 Wilms + neuroblastoma, 1 mamma adenoma (14yr)+ pheochromocytoma (19yr)  
1 Wilms 
1 neuroblastoma 
DeBaun et al., 2002 
 
 
92 
 
IC2                  1/39  
IC1                  4/10  
UPD                5/12 
No defect        6/31 
CDKN1C        not studied 
not specified 
Bliek et al., 2004
5
  
 
66 IC2                  2/27 
IC1                  6/9 
UPD                7/13
6 
No defect        3/17 
CDKN1C         not studied 
1 thyroid carcinoma (14yr), 1 hepatoblastoma 
6 Wilms 
4 Wilms, 1 adrenal carcinoma, 1 neuroblastoma, 1 hepatoblastoma, 1 pheochromocytoma, 1 leukemia, 1 mammary adenoma 
2 Wilms, 1 neuroblastoma 
Brioude et al., 2013
7 
 
407 IC2                  8/257 
IC1                  8/35 
UPD                14/81
8
 
No defect:       not studied 
CDKN1C        3/34 
2 neuroblastoma, 2 hepatoblastoma, 1 sarcoma, 1 rhabdomyosarcoma, 1 thyroid carcinoma, 1 melanoma 
8 Wilms tumor 
10 Wilms tumor, 2 adrenocortical carcinoma, 2 hepatoblastoma, 1 rhabdomyosarcoma, 1 neuroblastoma, 1 acute lymphoid leukemia 
 
1 neuroblastoma, 1 ganglioneuroma, 1 acute lymphoid leukemia 
Ibrahim et al.,2014
7,9,10 
 
637 IC2                  2/288 
IC1                  3/28 
UPD                4/99 
No defect        5/201 
CDKN1C         1/21
11
 
1 hepatoblastoma, 1 rhabdomyosarcoma 
3 Wilms 
1 Wilms, 3 hepatoblastoma 
3 Wilms, 1 adrenocortical carcinoma, 1 neuroblastoma 
1 Wilms 
Mussa et al., 2015
7,12 
 
318 IC2                  4/190 
IC1                  8/31 
UPD               13/87 
No defect        not studied 
CDKN1C        0/10
 
2 neuroblastoma, 1 rhabdomyosarcoma, 1 germinoma 
7 Wilms, 1 pancratoblastoma 
3 Wilms, 5 hepatoblastoma, 2 neuroblastoma, 1 pancreatoblastoma, 1 adrenal carcinoma, 1 hemangioteloma 
 
none 
Present study
13
 229 IC2                 3/114 
IC1                 6/19 
UPD               6/44 
No defect       4/52
14
 
CDKN1C        not studied 
2 Wilms, 1 hepatoblastoma 
6 Wilms 
3 Wilms,1 hepatoblastoma, 1 myopepithelial cell carcinoma (13 yr), 1 pheochromocytoma 
3 Wilms, 1 Wilms + 1 hepatoblastoma+ 1 rhabdomyosarcoma 
Pooled data
 
 
1971 IC2                 26/995   (2.6%) 
 
IC1                 41/146   (28%) 
UPD               59/368   (16%)
15
 
 
No defect      23/342   (6.7%)
16
 
CDKN1C        5/72       (6,9%) 
All                  155/1923  (8%) 
2 Wilms, 7 hepatoblastoma, 3 thyroid ca, 5 rhabdomyosarcoma, 1 sarcoma, 4 neuroblastoma, 1 melanoma, 1 gonadoblastoma, 1 
germinoma, 1 not specified 
35 Wilms, 1 ganglioneuroma, 4 not specified, 1 pancratoblastoma 
29 Wilms, 13 hepatoblastoma, 1 pancreatoblastoma, 1 hemangiotheloma, 4 adrenocortical carcinoma, 2 mammary adenoma, 1 
rhabdomyosarcoma, 1 myoepithelial cell carcinoma, 5 neuroblastoma, 3 pheochromocytoma, 2 ALL, 5 not specified
 
14 Wilms, 1 hepatoblastoma, 1 rhabdomyosarcoma, 2 neuroblastoma, 1adrenocortical carcinoma, 6 not specified
 
1 Wilms, 2 neuroblastoma,1 ganglioneuroma, 1 acute lymphatic leukemia  
 
1
 only 59 of 125 patients evaluated for IC2 
2
 only 67 have been completely evaluated 
4
 6 tumors in 4 patients 
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3
 used other diagnostic criteria than the DeBaun or Elliott criteria 
5
 only patients from France included (Dutch patients included in present study) 
6
 10 tumors in 7 patients 
7
 only patients with a genetic defect included 
8 
17 tumors in 14 patients 
9
 includes patients reported by Engel et al., 2000 
10
 adapted figures as patients with isolated hemihypertrophy were excluded and additional data is included 
11
 not all patients have been tested for CDN1C (personal communication) 
12
 includes patients reported by Mussa et al., 2012 
13
 series include Bliek et al., 2001 and Dutch patients in Bliek et al., 2004 
14
 6 tumors in  4 patients 
15 
67 tumors in 59 patients 
16 
25 tumors in 23 patients 
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Table IV.  Age at detection of Wilms tumors and other tumors in cohorts of individuals with Beckwith-Wiedemann syndrome. 
Study Mean Age Median Age Other data 
 All 
tumors 
Wilms 
tumor 
Hepato- 
blastoma 
All 
tumors 
Wilms 
tumor 
Hepato- 
blastoma 
 
Green et al. 1993     26m  eldest age Wilms 7.9 yr 
DeBaun and Tucker 1998 14m      5 hepatoblastoma, 6 Wilms, 2 
neuroblastoma 
Gaston et al.  2001 
- IC2 
- IC1 
- pUPD 
- no defect 
58m 
132m 
25m 
79m 
12m 
34.5m 
- 
25m 
55m 
12m (n=1) 
 18m 24m  1 Wilms 12 yr, 1 thyroid 
carcinoma 11 yr, 1 mamma 
adenoma 14yr.  
1 pheochromocytoma 19yr 
Neuroblastoma at 4m, 10m 
Clericuzio et al. 2003   6 m   5 m  
Mussa et al. 2012       1 Wilms 10 yr (bilateral) 
Brioude et al. 2013 
- IC2 
- IC1 
- pUPD 
24m 
35m 
24m 
16m 
21m 
- 
24m 
17m 
3m 
1.5m 
- 
5m 
21m 
28.5 
24m 
16m 
22,5m 
- 
24m 
18,5m 
3m 
1.5m 
- 
5m 
1 Wilms 12 yr, 1 ALL at 120m, 
1 sarcoma at 74m 
1  thyroid carcinoma at 75m 
3 neuroblastoma at <1 m, 4m, 6m 
Trobaugh-Lotrarario et al. 
2014 
  8m   6m eldest age hepatoblastoma 30m 
Ibrahim et al. 2014 
- IC2 
- IC1 
- pUPD 
- no defect 
24m 
- 
37.5m 
25.5m 
32m 
33m 
- 
37.5m 
24m (n=1) 
32m 
8m 
- 
- 
8m 
- 
24m 
- 
37.5m 
6m 
36m 
36m 
- 
37.5m 
24m (n=1) 
36m 
6m 
- 
- 
6m 
- 
 
Present study 
- IC2 
- IC1 
- pUPD 
- no defect 
28m 
39m 
31m 
27.5m 
41m 
30m 
11m 
31m 
34m 
41m 
11.5m 
14m (n=1) 
- 
9m   (n=1) 
- 
18m 
14m 
33m 
57m 
41m 
18m 
14m 
33m 
30m 
41m 
12m 
 
eldest age Wilms 5.5 yr 
eldest age hepatoblastoma 30m 
All studies 
- IC2 
- IC1 
- pUPD 
- no defects 
28m 
38m 
28m 
29m 
32m 
28m 
11m 
25m 
29m 
32m 
7m 
6m 
- 
7m 
- 
14m 
13m 
24m 
12m 
30m 
24m 
11m 
24m 
20m 
30m 
6m 
2m 
- 
6m 
- 
6 Wilms >5yr 
all hepatoblastoma <30m 
all neuroblastoma <12m 
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Table V. Overview of suggested screening protocols taking molecular subgroups into 
account. 
 
Publication Abdominal ultrasound AFP Other 
Frequency Duration Frequency Duration 
Rump et al., 2005 
  IC2 
  IC1 
  pUPD 
  CDKN1C 
 
indicated for hepatoblastoma 
indicated for Wilms 
indicated for Wilms 
n.m. 
 
n.m.
1 
n.m. 
n.m. 
 
 
 
 
 
 
Santiago et al., 2008 
  IC2 
  IC1 
  pUPD 
  CDKN1C 
 
once at age 3m 
1 x 6m 
1 x 6m 
once at age 3m 
 
once 
0-6 yr 
0-6 yr  
once 
 
- 
1 x 3m 
1 x 3m 
- 
 
 
0-4 yr 
0-4 yr 
 
physical exam  1 x 1m for 0-1yr and 1 x 3m for 2-5yr  
physical exam  1 x 3m for 0-6yr  
physical exam  1 x 3m for 0-6yr  
physical exam  1 x 1m for 0-1yr and 1 x 3m for 2-5yr  
Brioude et al., 2013 
  IC2 
   
  IC1 
  pUPD 
  CDKN1C 
 
once at diagnosis; if hemihyperplasia or 
organomegaly
2
 1 x 3m 
1 x 3m 
1 x 3m 
1 x 3m 
 
0-6 yr 
 
0-6 yr  
0-6 yr 
0-6 yr 
 
 
  
physical exam 1 x 1m for 0-2yr and 1 x 3-6m for 2-6yr  
 
physical exam 1 x 1m for 0-1yr, 1 x 3m for 1-6yr, 1 x yr after 6yr 
physical exam 1 x 1m for 0-1yr, 1 x 3m for 1-6yr, 1 x yr after 6yr 
physical exam 1 x 1m for 0-1yr, 1 x 3m for 1-6yr, 1 x yr after 6yr 
Mussa et al., 2015  
  IC2 
  IC1 
  pUPD 
  CDKN1C 
 
“Questionable” 
1 x 3-6m 
n.m. 
n.m. 
 
 
0-3 yr 
 
“Questionable” 
- 
indicated 
- 
 
 
 
n.m. 
 
 
 
no indication on frequency provided 
Cooper et al., 2005 
  IC2 
  IC1 
  pUPD 
  CDKN1C 
 
Indicated for hepatoblastoma 
indicated for Wilms 
indicated for Wilms  
n.m. 
 
n.m. 
n.m. 
n.m. 
 
- 
- 
- 
- 
 
 
 
 
 
Present proposal 
  IC2 
  IC1 
  pUPD 
  CDKN1C 
 
  no detectable defect 
 
not indicated 
indicated for Wilms 1 x 3m 
indicated for Wilms and hepatoblastoma 1 x 3m 
facultative for Wilms and hepatoblastoma 1 x 3m  
facultative for neuroblastoma 1 x 3m 
indicated for Wilms and hepatoblastoma 1 x 3m 
 
 
0-4yr 
0-4yr
3 
0-4yr
3 
0-2yr 
0-4yr
3 
not indicated  physical exams by parent(s) not indicated 
 
 
 
facultative: urinary VMA/HVA excretion 1 x 3m for 0-2yr 
 
 
1
  n.m. = not mentioned   
2
  enlarged liver or spleen or kidney  
3
  For hepatoblastoma indicated till 36m but in practice it will be performed till 48m together with Wilms screening 
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Table S-I. Unusual morphological signs in 244 individuals with Beckwith-Wiedemann 
syndrome. 
 
Sign    Number of individuals showing sign 
Trigonocephaly    1 
Plagiocephaly    1 
Dolichocephaly    2 
Wide anterior fontanel   1 
Low frontal hairline   2 
Prominent forehead   3 
Wide eyebrows    1 
Wide palpebral fissures   1 
Blepharophimosis    1 
Strabismus    3 
Periorbital fullness    2 
Downward slanted palpebral fissures  2 
Upward slanted palpebral fissures  3 
Epicanthi     6 
Hyperetelorism    3 
Wide nasal bridge    4 
Depressed nasal bridge   4 
Short nose    3 
Broad nasal tip    2 
Upturned nasal tip    1 
Wide nares    1 
Flat face     1 
Flat malae    1 
Full cheeks    1 
Smooth philtrum    2 
Long philtrum    1 
Thin vermillions    1 
Full lips     1 
Highly arched palate   1 
Low set ears    1 
Posteriorly rotated ears   1 
Prominent ears    1 
Deep flexion creases hands   1 
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Single flexion crease hand   1 
Genua valga    1 
Partial syndactyly toes 2+3   2 
Hypermobile joints    1 
Pectus carinatum    1 
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Supplemental Table S-2.  Correlations between hemihyperplasia and enlarged visceral organs and 
the presence of Wilms tumors for the various molecular genetic subgroups of Beckwith-
Wiedemann syndrome. 
 
Molecular Physical sign   Frequency Wilms  Fisher’s exact test 
subgroup     tumor 
IC2  hemihyperplasia   1/33    
  no hemihyperplasia  1/72    
  all    2/105   0.532 
  splenomegaly   0/7    
  no splenomegaly   2/88    
  all    2/95   1 
  hepatomegaly   0/18    
  no hepatomegaly   2/82    
  all    2/100   1 
  hepato- or splenomegaly  0/29    
  no hepato- or splenomegaly  2/85    
  all    2/114   1 
  hemihyperplasia + hepato- 
  or splenomegaly   0/8 
  no hemihyperplasia + hepato- 
  or splenomegaly   2/106 
  all    2/114   1 
  nephromegaly   0/14    
  no nephromegaly   2/84    
  all    2/98   1 
IC1  hemihyperplasia   3/11    
  no hemihyperplasia  3/7    
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  all    6/18   0.672 
  splenomegaly   1/3    
  no splenomegaly   5/16    
  all    6/19   1 
  hepatomegaly   1/4    
  no hepatomegaly   5/15    
  all    6/19   1 
  hepato- or splenomegaly  3/8    
  no hepato- or splenomegaly  3/11    
  all    6/19   1 
  hemihyperplasia + hepato- 
  or splenomegaly   1/4 
  no hemihyperplasia + hepato- 
  or splenomegaly   5/15 
  all    6/19   1 
  nephromegaly   3/7    
  no nephromegaly   3/12    
  all    6/19   0.617 
pUPD  hemihyperplasia   0/36    
  no hemihyperplasia  2/6    
  all    2/42   0.017* 
  splenomegaly   1/4    
  no splenomegaly   1/30    
  all    2/34   0.225 
  hepatomegaly   1/7    
  no hepatomegaly   1/27    
  all    2/34   0.374 
  hepato- or splenomegaly  2/18    
  no hepato- or splenomegaly  1/26    
  all    3/44   0.558 
  hemihyperplasia + hepato- 
  or splenomegaly   0/15 
  no hemihyperplasia + hepato- 
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  or splenomegaly   3/29 
  all    3/44   0.540 
  nephromegaly   2/17    
  no nephromegaly   1/21    
  all    3/38   0.577 
No defect hemihyperplasia   4/17    
  no hemihyperplasia  0/28    
  all    4.45   0.016* 
  splenomegaly   2/6    
  no splenomegaly   1/38    
  all    3/44   0.045 
  hepatomegaly   2/13    
  no hepatomegaly   1/29    
  all    3/42   0.222 
  hepato- or splenomegaly  3/19    
  no hepato- or splenomegaly  1/33    
  all    4/52   0.132 
  hemihyperplasia + hepato- 
  or splenomegaly   3/6 
  no hemihyperplasia + hepato- 
  or splenomegaly   1/46 
  all    4/52   0.003* 
  nephromegaly   3/16    
  no nephromegaly   1/28    
  all    4/44   0.129 
  
  
Page 40 of 40
John Wiley & Sons, Inc.
American Journal of Medical Genetics: Part A
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
